Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing. Go→
News, articles and issues specific to clinical trial practice and implementation at the investigative site level. Go→
News, developments and strategies related to eClinical, data management, data collection, ePRO, and more information technology used in the drug development chain. Go→
News, articles and issues specific to laboratories role in the clinical trial, including ECG, imaging, genotyping, tissue samples and more. Go→
News, developments and strategies for clinical trials conduct in relation to the FDA, EMEA and other global regulatory authorities overseeing the drug development industry. Go→
News, articles and strategies related to clinical trial design which impact postmarketing studies, therapeutic areas, adaptive trials, statistics, protocols and more. Go→
|
|
For Smokers, Low Levels of Vitamin D May Lead to Cancer
Publish date: Mar 15, 2013
![]()
PR Newswire WASHINGTON, March 15, 2013
WASHINGTON, March 15, 2013 /PRNewswire/ -- New research appearing
online today in
Clinical Chemistry
, the journal of AACC, shows that decreased levels
of vitamin D may predispose smokers to developing tobacco-related cancer. This study illustrates that simple vitamin D blood
tests and supplements have the potential to improve smokers' health. (Logo: http://photos.prnewswire.com/prnh/20121206/PH25333LOGO
) In the U.S. alone, cigarette smoking accounts for more deaths annually than HIV, illegal drugs, alcohol, motor vehicle
injuries, suicides, and murders combined. It is the primary causal factor for at least 30% of all cancer deaths, and can lead
to multiple kinds of cancer, including bladder, cervical, esophageal, head and neck, kidney, liver, lung, pancreatic, and
stomach, as well as myeloid leukemia. According to the Centers for Disease Control and Prevention, the healthcare expenditures
and productivity losses due to smoking cost the economy approximately $193 billion per year.
In this paper, Afzal et al. measured plasma vitamin D levels in blood samples collected in 1981–1983 from 10,000
Danes from the general population. Researchers then followed the study participants for up to 28 years through the Danish
Cancer Registry. Of the participants, 1,081 eventually developed a tobacco-related cancer. The authors determined that the
median vitamin D concentration among these participants was only 14.8 ng/mL, versus the higher 16.4 ng/mL median concentration
found for all participants together. These results show for the first time that the risk of tobacco-related cancers as a group is associated with lower concentrations
of vitamin D. The data also indicate that tobacco smoke chemicals may influence vitamin D metabolism and function, while vitamin
D may conversely modify the carcinogenicity of tobacco smoke chemicals. If further research confirms this, it would be consistent
with previous studies demonstrating the anti-tumorigenic effects of vitamin D derivatives, as well as the correlation of vitamin
D deficiency with favorable cancer-forming conditions and increased susceptibility to tobacco smoke carcinogens. Interestingly,
though, low vitamin D levels were not connected with risk of other cancer types. "Our analyses show that the association between lower concentrations of plasma vitamin D and higher risk of cancer may
be driven by tobacco-related cancer as a group, which has not been shown before," stated author Borge G. Nordestgaard, MD,
DMSc, in the paper. "This is important for future studies investigating the association between plasma vitamin D and risk
of cancer." About AACC
Clinical Chemistry is the leading international journal of clinical laboratory science, providing 2,000 pages per year
of peer-reviewed papers that advance the science of the field. With an impact factor of 7.9, Clinical Chemistry covers
everything from molecular diagnostics to laboratory management.
Molly Polen
SOURCE AACC
|
|